About Leading Edge Bio

Leading Edge Bio is a strategic advisory firm that helps biotechnology, pharmaceutical, and AI-enabled life sciences companies accelerate innovation through corporate strategy, business development, licensing, commercialization, and strategic partnerships.

The firm specializes in bridging scientific innovation with commercial execution, helping clients evaluate strategic opportunities, establish high-value partnerships, and position technologies for long-term growth. Engagements are tailored to each client's objectives and span the full innovation lifecycle—from discovery platforms and therapeutic assets to enabling technologies and AI-driven solutions.

Leading Edge Bio partners selectively with executive teams, founders, investors, and technology innovators on initiatives involving corporate strategy, external innovation, portfolio planning, licensing, and enterprise partnerships. The firm's approach combines scientific insight, commercial strategy, and disciplined execution to help organizations create sustainable competitive advantage and maximize enterprise value.

As the life sciences industry continues to evolve, Leading Edge Bio advises organizations developing next-generation technologies, including AI-enabled drug discovery, advanced research platforms, and emerging therapeutic modalities, helping position scientific innovation for commercial success.

About John Q. Leonard

John Q. Leonard is a senior biopharma executive with more than 25 years of experience leading corporate strategy, business development, licensing, and commercial growth across biotechnology, pharmaceutical, and life sciences organizations.

Beginning his career as a research scientist at GSK and Eli Lilly before transitioning into executive leadership, John has built a career helping innovative companies translate scientific breakthroughs into strategic partnerships and sustainable enterprise value.

His leadership experience includes global commercial strategy, antibody discovery, AI-enabled drug discovery technologies, preclinical research services, cell and gene therapy, oncology, neuroscience, immunology, and precision medicine. He has advised organizations ranging from venture-backed startups to multinational pharmaceutical companies while cultivating a global network of more than 5,000 life sciences executives, investors, researchers, and industry leaders.

John earned an MBA from the University of Southern California Marshall School of Business and a Bachelor of Science in Biochemistry from North Carolina State University.

Core Areas of Expertise

Corporate Strategy & Commercial Growth
Strategic Partnerships & Licensing
Business Development & External Innovation
Corporate Development & Portfolio Strategy
AI-Enabled Drug Discovery & Research Technologies
Antibody Discovery & Therapeutic Platforms
Preclinical Development & CRO Strategy
Technology Commercialization
Competitive Positioning & Market Strategy
Executive Advisory